Our study demonstrates that targeting GLUT1 via BAY-876 to kill HNSCC cells, particularly in combination with T2R agonists, is a potential novel treatment strategy worth exploring further in future translational studies. This evidence concerns the gene SLC2A1 and head and neck squamous cell carcinoma.